One Sure Formula for Controversy (WSJ): New York City’s “Latch On NYC” initiative encouraging breast feeding — so far embraced by 27 of 40 maternity hospitals in the city — has ignited fierce debate.

FDA Figure Is Under Fire (WSJ): A Food and Drug Administration scientist is being criticized by some breast-cancer doctors and others in the agency for blocking approval of potentially more precise digital mammography machines for several years….

Medical Devices in Hospitals Go Wireless (WSJ): Easier hospital-patient monitoring, fewer tubes in ERs and more home monitoring may result from an FCC vote Thursday to open up spectrum to the wireless devices.

Long-Lasting Birth Control Cuts Pregnancy Rate (WSJ): A study of about 7,500 women published in the New England Journal of Medicine showed long-lasting forms of contraception like intrauterine devices were about 20 times more effective than pills, patches and vaginal rings….

Study Damps Fears on Autism Change (WSJ): A controversial change to the criteria for diagnosing autism turns out to “almost always” catch children diagnosed under the current guidelines, new data show.

FDA Panel Considers HIV Drug For New Use (WSJ): Gilead Sciences has asked the Food and Drug Administration to consider approving its HIV treatment Truvada as a preventive medicine—a potential first—that could keep people from contracting the virus. An advisory panel will vote Thursday.

Here’s what’s making health news this morning: Autism Risk Tied to Mom’s Weight and Health During Pregnancy (WSJ): University of California, Davis, researchers find mtohers who are obese or have diabetes during pregnancy are at increased risk of having a child with autism. FDA Approves Alzheimer’s Test (WSJ): Test by Eli Lilly & Co uses [...]

Health-Law Case Puts Roberts in Crucible (WSJ): The chief justice left himself room to uphold the health-care overhaul and stay in line with his comments made during this week’s oral arguments, though he seem more skeptical of the law than Justice Anthony Kennedy.

J&J Settles With Texas: Johnson & Johnson said it would pay $158 million to settle claims by Texas that the company promoted its antipsychotic drug Risperdal for unapproved uses, resulting in overcharges to the state’s Medicaid program, the WSJ reports. J&J said the settlement, to be paid to a plaintiff who filed a whistleblower suit and his attorneys, the state of Texas and the U.S. government, “will circumvent potentially and costly appellate activities” ….

ADHD Diagnosis: New American Academy of Pediatrics treatment guidelines for attention deficit hyperactivity disorder say ADHD can be diagnosed in kids as early as age four, and that Ritalin and similar drugs are an appropriate treatment even for those youngest kids with persistent symptoms when behavioral-management strategies don’t work, the WSJ reports. Many ADHD medications are only approved by the FDA for kids aged six and up, but physicians can use them off-label if they wish …